Results 81 to 90 of about 412,640 (216)
To systematically compare the immunogenicity differences between measles-mumps-rubella combined (MMR) vaccine and measles-rubella combined (MR) vaccine following first dose vaccination in 8–9-month-old infants, with emphasis on evaluating the response ...
Xue-feng Liang +3 more
doaj +1 more source
Sero-epidemiology of rubella in the urban population of Addis Ababa Ethiopia [PDF]
We conducted a community-based cluster sample survey of rubella sero-epidemiology in Addis Ababa, Ethiopia in 1994. Among 4666 individuals for whom complete data were available, rubella antibody prevalence was 91% (95% confidence interval: 90, 92).
Nigatu, Wondatir +6 more
core +1 more source
INTRODUCTION. Spontaneous mutations often arise and accumulate in the genome of RNA-containing viruses, for example measles, rubella and mumps. Modern requirements for the production of vaccine products containing live vaccine viruses suggest control of ...
A. I. Zheltukhina +13 more
doaj +1 more source
Controversies in Vaccination with Measles, Mumps, Rubella (MMR) Vaccine [PDF]
Many people remember the extensive adverse publicity surrounding pertussis vaccine in the 1970s which led to public concern about the safety of vaccines. Subsequently, follow‐up indicated no causal link between pertussis vaccination and brain damage although the risk of recurrent collapse (shock‐like syndrome or so‐called hypotonic‐hyporesponsive ...
openaire +1 more source
Recognising and Addressing Vaccine Hesitancy That Is Not Always Directly Voiced by a Child's Parents
Acta Paediatrica, Volume 115, Issue 11, Page 2514-2517, November 2026.
Alessandro Diana
wiley +1 more source
Rubella : also known as German measles [PDF]
Rubella, sometimes called \u201cGerman measles,\u201d is a contagious disease caused by a virus. Unlike measles, rubella almost never causes serious illness or complications in infants and young children.
core
A Case of Genital and Extragenital Warts Unresponsive to Immunotherapy Using Measles, Mumps, Rubella Vaccine. [PDF]
Achdiat PA +3 more
europepmc +1 more source
A total of 44 children aged between 15-18 months were randomly vaccinated either with a new measles-mumps-rubella (MMR) vaccine (Priorix, SmithKline Beecham) or a commercially available MMR vaccine (MMR-II, Merck) to compare the reactogenicity and
G Kanra, M Ceyhan, E Ozmert
doaj
Barriers to measles mumps rubella vaccine acceptance in the three southern border provinces of Thailand. [PDF]
Sirithammaphan U +2 more
europepmc +1 more source
Can We Justify Intralesional Immunotherapy with Measles-mumps-rubella Vaccine for Recalcitrant Facial Warts? [PDF]
Al-Mendalawi MD.
europepmc +1 more source

